Fibroblast growth factor-2

Drug Profile

Fibroblast growth factor-2

Alternative Names: Recombinant fibroblast growth factor-2; rFGF-2

Latest Information Update: 23 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Fibroblast growth factors
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Cardiovascular disorders; Peripheral arterial occlusive disorders

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 17 Jul 2002 This agent is still in active development
  • 14 Feb 2001 Two studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top